Gossamer Bio/$GOSS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
- Ticker
- $GOSS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 162
- Headquarters
- San Diego, United States
- Website
- www.gossamerbio.com
Gossamer Bio Metrics
BasicAdvanced
$67M
-
-$40.17
-
-
Price and volume
Market cap
$67M
52-week high
$309.60
52-week low
$8.29
Average daily volume
207K
Financial strength
Total debt to equity
-0.426
Interest coverage (TTM)
-10.02%
Profitability
EBITDA (TTM)
-106.996
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-159.49%
Operating margin (TTM)
-136.46%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$480,000
Management effectiveness
Valuation
Price to revenue (TTM)
0.573
Price to book
-0.71
Price to tangible book (TTM)
-0.71
Growth
Revenue change (TTM)
78.03%
Earnings per share change (TTM)
-26.95%
3-year earnings per share growth (CAGR)
-31.56%
What the Analysts think about Gossamer Bio
Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.
Analyst projections of the future price of Gossamer Bio stock.
Gossamer Bio Financial Performance
Revenues and expenses
Gossamer Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Gossamer Bio News
AllArticlesVideos

Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results
Benzinga4 days ago

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Business Wire2 months ago

Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Business Wire2 months ago
Funds containing Gossamer Bio
Fund name | Fund size | $GOSS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.01% |
Xtrackers S&P 500 Swap£XSPX | $9.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.